RIGL Stock Overview
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases.
No risks detected for RIGL from our risk checks.
Rigel Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.01|
|52 Week High||US$4.62|
|52 Week Low||US$1.80|
|1 Month Change||-25.28%|
|3 Month Change||-16.60%|
|1 Year Change||-44.93%|
|3 Year Change||-6.08%|
|5 Year Change||-15.90%|
|Change since IPO||-96.86%|
Recent News & Updates
Is Rigel Pharmaceuticals (NASDAQ:RIGL) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
|RIGL||US Biotechs||US Market|
Return vs Industry: RIGL underperformed the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: RIGL underperformed the US Market which returned -12.9% over the past year.
|RIGL Average Weekly Movement||11.9%|
|Biotechs Industry Average Movement||12.3%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: RIGL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: RIGL's weekly volatility (12%) has been stable over the past year.
About the Company
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19.
Rigel Pharmaceuticals Fundamentals Summary
|RIGL fundamental statistics|
Is RIGL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RIGL income statement (TTM)|
|Cost of Revenue||US$64.77m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.49|
|Net Profit Margin||-109.56%|
How did RIGL perform over the long term?See historical performance and comparison
Is Rigel Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: RIGL ($2.01) is trading below our estimate of fair value ($15.79)
Significantly Below Fair Value: RIGL is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: RIGL is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: RIGL is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RIGL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RIGL is overvalued based on its PB Ratio (50.9x) compared to the US Biotechs industry average (1.5x).
How is Rigel Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RIGL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: RIGL is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: RIGL's is expected to become profitable in the next 3 years.
Revenue vs Market: RIGL's revenue (31.2% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: RIGL's revenue (31.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RIGL's Return on Equity is forecast to be high in 3 years time
How has Rigel Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RIGL is currently unprofitable.
Growing Profit Margin: RIGL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RIGL is unprofitable, but has reduced losses over the past 5 years at a rate of 24.3% per year.
Accelerating Growth: Unable to compare RIGL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RIGL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: RIGL has a negative Return on Equity (-1248.29%), as it is currently unprofitable.
How is Rigel Pharmaceuticals's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: RIGL's short term assets ($138.9M) exceed its short term liabilities ($59.2M).
Long Term Liabilities: RIGL's short term assets ($138.9M) exceed its long term liabilities ($83.1M).
Debt to Equity History and Analysis
Debt Level: RIGL has more cash than its total debt.
Reducing Debt: Insufficient data to determine if RIGL's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RIGL has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: RIGL has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 23.8% each year.
What is Rigel Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RIGL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RIGL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RIGL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RIGL's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as RIGL has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Raul Rodriguez (60 yo)
Mr. Raul R. Rodriguez has been the Chief Executive Officer of Rigel Pharmaceuticals, Inc., since November 2014 and has been its President since May 2010. Mr. Rodriguez served as Chief Operating Officer at...
CEO Compensation Analysis
Compensation vs Market: Raul's total compensation ($USD3.43M) is above average for companies of similar size in the US market ($USD2.59M).
Compensation vs Earnings: Raul's compensation has increased whilst the company is unprofitable.
Experienced Management: RIGL's management team is considered experienced (4.8 years average tenure).
Experienced Board: RIGL's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Rigel Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: Rigel Pharmaceuticals, Inc.
- Ticker: RIGL
- Exchange: NasdaqGS
- Founded: 1996
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$345.825m
- Shares outstanding: 172.05m
- Website: https://www.rigel.com
Number of Employees
- Rigel Pharmaceuticals, Inc.
- 1180 Veterans Boulevard
- South San Francisco
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/21 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.